Safety and efficacy of obinutuzumab in Chinese patients with B-cell lymphomas: a secondary analysis of the GERSHWIN trial

Yan Qin¹, Yuqin Song², Zhixiang Shen³, Xin Du⁴, Wei Ji⁵, Wanling Hsu⁶, Jun Zhu² and Yuankai Shi¹*

Abstract

Background: Patients with relapsed/refractory B-cell lymphomas have limited treatment options. GERSHWIN is an open-label, single-arm, phase Ib study of obinutuzumab monotherapy in Chinese patients with histologically documented CD20⁺ relapsed/refractory chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), or follicular lymphoma (FL). The primary outcome measure of pharmacokinetics has been previously reported. We now present data on the secondary endpoint measures (e.g., safety, efficacy, and pharmacodynamics).

Methods: Patients received 1000 mg obinutuzumab intravenously on days 1, 8, and 15 of cycle 1 (CLL patients; first dose split over 2 days), and on day 1 of cycles 2–8. Each cycle lasted for 21 days; the treatment period was 24 weeks. All subjects receiving at least one dose of obinutuzumab were included in the analysis of safety, efficacy, as well as pharmacodynamics.

Results: A total of 48 patients (>18 years of age) were enrolled (CLL: 12; DLBCL: 23; FL: 13). The subjects received a median of two lines of anticancer treatment prior to the enrollment. Thirty-five patients (72.9%) had at least one adverse event (AE). The most frequent AE was infusion-related reactions (15 patients; 31.3%), followed by pyrexia (11 patients; 22.9%). Treatment-related AEs were reported in 28 patients (58.3%), and included one death (interstitial lung disease). End-of-treatment (EoT) response rate was 33.3%. Best overall response rate was 47.9%. Most CLL patients achieved a partial response at EoT (58.3%). CD19⁺ depletion occurred in 75.0% of the patients with CLL, and all patients with FL and DLBCL.

Conclusions: The safety and efficacy of obinutuzumab monotherapy in Chinese patients with B-cell lymphomas were similar to that observed in previous studies in non-Chinese patients; no new safety signals were observed.

Clinical trial registration ID NCT01680991

Keywords: Obinutuzumab, B-cell lymphoma, Chronic lymphocytic leukemia, Chinese patients

Background

B-cell lymphoproliferative disorders range from slow-growing indolent diseases, such as chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL), to more aggressive diseases, such as diffuse large B-cell lymphoma (DLBCL). The incidence of CLL in the Chinese population is approximately one-tenth of that in Western countries [1]. In a nationwide collaborative study of 10,002 lymphoma patients by Li and colleagues in [2], DLBCL accounted for 50.2% of all cases of common B-cell lymphoma in China; FL and CLL/small lymphocytic leukemia accounted for 8.3% and 6.4%, respectively. Most B-cell lymphomas are characterized by the expression of CD20⁺, a membrane antigen implicated in cell-cycle initiation and differentiation [3]. Anti-CD20⁺ monoclonal antibodies, such as rituximab, have been shown to be effective for B-cell lymphomas when used in combination with chemotherapeutic agents [4–7].
However, many patients eventually relapse or become refractory upon repeated exposure. Thus, there is an ongoing need to develop more therapies that could effectively prolong remission and/or improve survival.

Obinutuzumab (GA101; GAZYVA/GAZYVARO) is a novel glycol-engineered type II anti-CD20\(^+\) monoclonal antibody, and has shown promising activity in phase Ib/II studies in patients with B-cell malignancies [8–11]. In stage II of the pivotal phase III CLL11 study in previously untreated CLL patients receiving background chlorambucil, obinutuzumab significantly prolonged progression-free survival (PFS) in comparison to rituximab (median PFS 29.2 vs. 15.4 months; hazard ratio 0.40; 95% confidence interval, 0.33–0.50, \(P < 0.001\)) [12, 13]. Based on results from the CLL11 study, obinutuzumab in combination with chlorambucil has been approved for the treatment of patients with previously untreated CLL in more than 60 countries [14, 15]. Obinutuzumab has also shown activity in patients with relapsed CD20\(^+\) indolent non-Hodgkin lymphoma (NHL). In the phase II GAUSS study in relapsed CD20\(^+\) indolent NHL patients, obinutuzumab produced a higher overall response rate than rituximab (44.6% vs. 33.3%; \(P = 0.08\)) [16]. The efficacy and safety of obinutuzumab has also been assessed in the phase III GADOLIN study in patients with rituximab-refractory indolent NHL [17]. In this study, obinutuzumab plus bendamustine was associated with a 45% reduction in the risk of disease progression or death (assessed by an independent review committee) vs. bendamustine induction alone. Based on the results from GADOLIN, obinutuzumab has been approved for rituximab-refractory FL in the US and Europe [14, 15]. In all three trials, the adverse events (AEs) related to obinutuzumab alone, or in combination with other chemotherapeutic agents, were generally manageable.

To date, no ethnic sensitivity associated with the use of obinutuzumab has been reported. We have completed a trial (GERSHWIN; trial registration ID: NCT01680991) to evaluate obinutuzumab in Chinese patients with CD20\(^+\) relapsed/refractory malignant B-cell lymphomas. The primary outcome measure of pharmacokinetic profile of obinutuzumab following repeated intravenous dosing has been previously reported [18]. Here, we report the results of secondary outcome measures: safety, tolerability, efficacy, and pharmacodynamics.

**Patients and methods**

**Study design and treatment**

GERSHWIN was an open-label, multicenter, single-arm, phase Ib study, conducted in four sites in China between September 6, 2012 and August 15, 2013. The study was conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonization guidelines for Good Clinical Practice. Approval from Institutional Review Boards and/or Independent Ethics Committees was obtained before the trial started.

Patients received a maximum of eight treatment cycles (24 weeks), each lasting for 21 days. On day 1 of each cycle, obinutuzumab was given intravenously at a dose of 1000 mg. In cycle 1, additional doses of obinutuzumab were administered on days 8 and 15. In patients with CLL, the first infusion of obinutuzumab on cycle 1 was given as a split dose over 2 days (100 mg at a rate of 25 mg/h over 4 h on day 1; 900 mg starting at 50 mg/h on day 2, increasing by 50 mg/h every 30 min, to a maximum of 400 mg/h) to minimize the risk of infusion-related reactions (IRRs). For the first infusion in patients with NHL, obinutuzumab was administered at an initial rate of 50 mg/h, and increased by 50 mg/h every 30 min to a maximum of 400 mg/h if there were no signs of IRRs. If the first obinutuzumab infusion was well tolerated by all study subjects, subsequent infusions were initiated at 100 mg/h and increased by 100 mg/h increments every 30 min to a maximum of 400 mg/h.

**Study population**

Adult patients (> 18 years of age) with histologically documented CD20\(^+\) relapsed/refractory CLL, DLBCL, or FL; an Eastern Cooperative Oncology Group performance status of 0 or 1; and a life expectancy of > 6 months were eligible. With the exception of CLL, all patients had at least one bidimensionally measurable lesion (> 1.5 cm in its largest dimension by computed tomography). For patients with CLL, circulating lymphocyte cell assessments were an acceptable method of measurement.

To be eligible, patients with DLBCL or FL must have relapsed after, or had been refractory to, at least one standard chemotheraphy, with or without rituximab. CLL patients must have relapsed after, or had been refractory to at least one chemotherapy regimen. Relapse was defined as disease recurrence after any documented history of response [complete response (CR), CR with incomplete bone marrow recovery (CRi; CLL patients only) or partial response (PR)] that lasted ≥ 6 months. Refractoriness was defined as progression or stable disease (SD) on treatment, or any response that was followed by progression < 6 months after treatment. All patients provided written informed consent to participate in the study.

Key exclusion criteria included the following: use of any investigational monoclonal antibody therapy within 6 months before the trial started; use of any anticancer vaccine; prior treatment with rituximab or radioimmunotherapy within 3 months of study entry; history of severe anaphylactic reactions to humanized or murine monoclonal antibodies; central nervous system lymphoma; and...
history of other malignancy or evidence of significant, uncontrolled concomitant diseases (including cardiovascular and pulmonary diseases). Full inclusion and exclusion criteria are shown in Additional file 1.

Study endpoints and procedures

Safety and tolerability

Safety assessments included AEs, serious AEs (SAEs) and AEs of special interest [AESI; e.g., IRRs, serious neutropenia, infections, and tumor lysis syndrome (TLS)]. AEs were summarized using the Medical Dictionary for Regulatory Activities system organ class, and graded using the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. Safety analyses included laboratory assessments (hematology, biochemistry, and urinalysis), vital signs, and electrocardiograms (ECGs); tests for immunogenicity [human antichimeric antibodies (HACA) and human antihuman antibodies (HAHA)] were also performed.

Efficacy

Treatment response was assessed according to the International Workshop to Standardize Response criteria for NHL [19], and 2008 Guidelines of the International Workshop on CLL [20]. End-of-treatment (EoT) response was assessed 1 month after the cycle 8, day 1 infusion, or for treatment withdrawals after cycle 4. For patients with CLL, a further confirmation of response was performed 2 months after EoT. Best overall response was assessed at any time point during the study, prior to new anti-lymphoma/leukemia therapy. For both EoT and best overall response, patients were regarded as responders if they demonstrated CR, CR unconfirmed (CRu), CRi (CLL patients only), or PR. Patients were considered to be non-responders if they demonstrated SD or progressive disease (PD), or were missing response assessments. Follow-up was carried out up to 1 year after the last dose.

Pharmacodynamics

CD19\(^+\) depletion was defined as CD19\(^+\) cell count < 0.07 \(\times 10^9\)/L; recovery was defined as \(\geq 0.07 \times 10^9\)/L. The duration of depletion was defined as the time between the first assessment of depletion and the first assessment when CD19\(^+\) B-cell count returned to at least the depletion level from baseline and was not followed by any further depletion time to recovery was defined as the time between the beginning of depletion and the first value after EoT that was \(\geq 0.07 \times 10^9\)/L, not followed exclusively by depleted values.

Analytical plan

Only descriptive analyses were performed; no formal hypothesis was tested.

Results

Patients

A total of 56 patients were screened for eligibility, among which 48 were enrolled (Fig. 1): 12 (25.0%) with CLL, 23 (47.9%) with DLBCL, and 13 (27.1%) with FL. Most patients had advanced disease [Binet B or C (CLL); Ann Arbor III or IV (NHL)] (Table 1). The median number of previous anticancer treatments was 2 or 3 depending on disease type. Twenty-eight subjects (58.3%; 28/48) completed the planned treatment. Obinutuzumab was discontinued in 17 (35.4%) patients during cycles 1–4 and three (6.3%) patients during cycles 5–8.

Safety and tolerability

All 48 enrolled patients received at least one dose of obinutuzumab and were included in the safety analysis. Median treatment duration was 20.8 weeks, with a median cumulative dose of 10,000 mg (Additional file 2). A total of 141 AEs were reported, mostly grade I–II (116/141, 82.3%). The number of patients who experienced at least one AE was 35 (CLL: 10/12, 83.3%; DLBCL: 18/23, 78.3%; FL: 7/13, 53.8%). The most common AE was IRR (CLL: 7/12, 58.3%; DLBCL: 5/23, 21.7%; FL: 3/13, 23.1%), with the highest rate in CLL patients (Additional file 3). Other common AEs included pyrexia (CLL: 6/12, 50.0%; DLBCL: 3/23, 13.0%; FL: 2/13, 15.4%) and cough (CLL: 4/12, 33.3%; DLBCL: 1/23, 4.3%; FL: 0). No patients withdrew from treatment as a result of treatment-related AEs.

Twenty-five grade III–V AEs were reported, with a seemingly higher rate in the CLL subgroup (CLL: 7/12, 58.3%; DLBCL: 5/23, 21.7%; FL: 3/13, 23.1%; Additional file 4). Infections and infestations were the most common grade III–V AEs across all three subgroups (CLL: 3/12, 25.0%; DLBCL: 2/23, 8.7%; FL: 2/13, 15.4%) (Additional file 4), with pneumonia accounting for two of the three events in the CLL subgroup. Grade III–V thrombocytopenia occurred in 16.7% (2/12) of the CLL patients. Neutropenia occurred in 15.4% (2/13) of the FL patients.

Thirteen SAEs were reported in nine patients, of which five were infections and infestations (CLL: 3/12, 25.0%; DLBCL: 1/23, 4.3%; FL: 1/13, 7.7%; Additional file 5). One SAE (grade III, pneumonia) led to the withdrawal of treatment in a patient with CLL, but was considered unrelated to treatment with obinutuzumab. In this case, pneumonia started on day 52, treatment was discontinued on day 66, and the patient was withdrawn from the study on day 90 (Table 2). The total rate of SAEs appeared higher in the CLL subgroup (Additional file 5). Six (6/48; 12.5%) patients reported a total of eight AESIs, including serious IRR (CLL: 1/12, 8.3%), serious neutropenia (CLL: 1/12, 8.3%; FL: 2/13, 15.4%), and serious infections (CLL: 3/12, 25.0%; DLBCL:...
1/23, 4.3%; FL: 1/13, 7.7%). The patient with a serious IRR also developed a serious infection (pneumonia). No cases of TLS were reported. Two deaths occurred during the follow-up period: one in the CLL subgroup [interstitial lung disease (interstitial pneumonia; no testing for Pneumocystis jiroveci was performed), which occurred 60 days after the last treatment dose] was considered treatment-related; the other after disease progression in the FL group was considered unrelated to treatment.

There were no clinically significant abnormal laboratory test results, ECGs, or vital signs during the treatment period. Three clinically significant abnormal ECGs were recorded prior to dosing. On cycle 1, day 1, two patients with CLL and one with DLBCL had detectable HACA. At the 6-month follow-up visit, one with FL had detectable HAHA.

No evidence of hepatitis B virus (HBV) reactivation was observed in any subject. Patients with CLL who were positive for hepatitis B core antibodies (anti-HBc) and
negative for hepatitis B surface antigen were eligible for participation if HBV DNA was undetectable, but were required to undergo monthly HBV DNA testing during the study period. Among the four patients with positive anti-HBc at screening, one patient refused to undergo monthly HBV DNA testing and withdrew from the study, one patient withdrew before the protocol requirement for HBV DNA testing was implemented, and the remaining two patients underwent monthly testing with no indication of HBV reactivation.

**Efficacy**

The efficacy dataset included all 48 patients. EoT and best overall response rate were higher in the CLL and FL subgroups than in the DLBCL subgroup (Table 3). In the CLL subgroup, the PR rate at EoT and best overall response rate were 58.3% (7/12) and 75.0% (9/12), respectively. In the FL subgroup, PR rate at EoT and best overall response rate were 46.2% (6/13) and 61.5% (8/13), respectively. In the DLBCL subgroup, EoT and best overall response rate were 13.0% (1/23 CRu; 2/23 PR) and 26.1%
### Table 2 Adverse events

| Variable | CLL (n = 12) | DLBCL (n = 23) | FL (n = 13) | Overall (n = 48) |
|----------|--------------|----------------|------------|-----------------|
| Number of patients with at least one AE | 10 (83.3) | 18 (78.3) | 7 (53.8) | 35 (72.9) |
| Number of AEs | 71 | 45 | 25 | 141 |
| Number of deaths | 1 (8.3) | 0 | 1 (7.7) | 2 (4.2) |
| Number of patients withdrawn from study due to an AE | 1 (8.3) | 0 | 0 | 1 (2.1) |
| Number of patients with at least one AE with fatal outcome | 1 (8.3) | 0 | 0 | 1 (2.1) |
| SAE | 5 (41.7) | 3 (13.0) | 1 (7.7) | 9 (18.8) |
| SAE leading to withdrawal from treatment | 1 (8.3) | 0 | 0 | 1 (2.1%) |
| Related SAE | 4 (33.3) | 1 (4.3) | 1 (7.7) | 6 (12.5) |
| AE leading to withdrawal from treatment | 1 (8.3) | 0 | 0 | 1 (2.1) |
| AE leading to treatment interruption | 4 (33.3) | 3 (13.0) | 2 (15.4) | 9 (18.8) |
| Related AE | 9 (75.0) | 12 (52.2) | 7 (53.8) | 28 (58.3) |
| Related AE leading to treatment interruption | 4 (33.3) | 3 (13.0) | 2 (15.4) | 9 (18.8) |
| Grade III–V AE (at greatest intensity) | 7 (58.3) | 5 (21.7) | 3 (23.1) | 15 (31.3) |

Percentages are based on n in the column headings. Multiple occurrences of the same AE in one individual are counted only once except for the ‘total number of AEs’ row, in which multiple occurrences of the same AE are counted separately.

Data are shown as n (%).

AE adverse event, CLL chronic lymphocytic leukemia, DLBCL diffuse large B-cell lymphoma, FL follicular lymphoma, SAE serious adverse event.

### Table 3 End of treatment and best overall response rate

| Variable | CLL (n = 12) | DLBCL (n = 23) | FL (n = 13) | Overall (n = 48) |
|----------|--------------|----------------|------------|-----------------|
| EoT response | Best overall response | EoT response | Best overall response | EoT response | Best overall response | EoT response | Best overall response |
| Responders, n (%) | 7 (58.3) | 9 (75.0) | 3 (13.0) | 6 (26.1) | 6 (46.2) | 8 (61.5) | 16 (33.3) | 23 (47.9) |
| Non-responders, n (%) | 5 (41.7) | 3 (25.0) | 20 (87.0) | 17 (73.9) | 7 (53.8) | 5 (38.5) | 32 (66.7) | 25 (52.1) |
| 95% CI for response rate | 27.67–84.83 | 42.81–94.51 | 2.78–33.59 | 10.23–48.41 | 19.22–74.87 | 31.58–86.14 | 20.40–48.41 | 33.29–62.81 |
| CR, n | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 95% CI | 0.00–26.46 | 0.00–26.46 | 0.00–14.82 | 0.00–14.82 | 0.00–24.71 | 0.00–24.71 | 0.00–7.40 | 0.00–7.40 |
| CRi, n | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 95% CI | 0.00–26.46 | 0.00–26.46 | 0.00–14.82 | 0.00–14.82 | 0.00–24.71 | 0.00–24.71 | 0.00–7.40 | 0.00–7.40 |
| CRu, n (%) | 0 | 0 | 1 (4.3) | 1 (4.3) | 0 | 0 | 1 (2.1) | 1 (2.1) |
| 95% CI | 0.00–26.46 | 0.00–26.46 | 0.11–21.95 | 0.11–21.95 | 0.00–24.71 | 0.00–24.71 | 0.05–11.07 | 0.05–11.07 |
| PR, n (%) | 7 (58.3) | 9 (75.0) | 2 (8.7) | 5 (21.7) | 6 (46.2) | 8 (61.5) | 15 (31.3) | 22 (45.8) |
| 95% CI | 27.67–84.83 | 42.81–94.51 | 1.07–28.04 | 7.46–43.70 | 19.22–74.87 | 31.58–86.14 | 18.66–46.25 | 31.37–60.83 |
| SD, n (%) | 1 (8.3) | 1 (8.3) | 2 (8.7) | 6 (26.1) | 4 (30.8) | 4 (30.8) | 7 (14.6) | 11 (22.9) |
| 95% CI | 0.21–38.48 | 0.21–38.48 | 1.07–28.04 | 10.23–48.41 | 9.09–61.43 | 9.09–61.43 | 6.07–27.76 | 12.03–37.31 |
| PD, n (%) | 2 (16.7) | 0 | 15 (65.2) | 9 (39.1) | 3 (23.1) | 1 (7.7) | 20 (41.7) | 10 (20.8) |
| 95% CI | 2.09–48.41 | 0.00–26.46 | 42.73–83.62 | 19.71–61.46 | 5.04–53.81 | 0.19–36.03 | 27.61–56.79 | 10.47–34.99 |
| Missing or non-evaluable, n (%) | 2 (16.7) | 2 (16.7) | 3 (13.0) | 2 (8.7) | 0 | 0 | 5 (10.4) | 4 (8.3) |

95% CI for rates were constructed using Clopper–Pearson method. Patients were classified as missing or non-evaluable if no post-baseline response assessments were available or all post-baseline response baseline assessments were un-evaluable.

CLL chronic lymphocytic leukemia, CI confidence interval, CR complete response, CRi CR with incomplete bone marrow recovery (CRi; CLL patients only), CRu CR unconfirmed, DLBCL diffuse large B-cell lymphoma, EoT end of treatment, FL follicular lymphoma, PR partial response, SD stable disease.
investigators in the current study during previous clinical
AEs during obinutuzumab therapy gained by some of the
measures to prevent the development of IRR and other
experienced an IRR [23]. Awareness of recommended
B-cell recovery (CD19+ B-cell count ≥ 0.07 × 10^9/L).
One patient with CLL and one with FL who experienced
B-cell recovery had PD: time to recovery was 419 days
(CLL) and 331 days (FL), respectively. For the three
patients with CLL who did not have PD, the median time
to recovery was 182 days, and for DLBCL (one patient
only), it was 515 days.

Pharmacodynamics
CD19+ B-cell depletion (count < 0.07 × 10^9/L) occurred in
75.0% (9/12) with CLL, 100% (13/13) of the patients with
FL, and 100% (23/23) with DLBCL. The FL subgroup
had the longest median duration of depletion, 465 days,
compared with 244 days for CLL and 92 days for DLBCL.
Subsequently, 33.3% (4/12) of patients with CLL, 7.7%
(1/13) with FL, and 4.3% (1/23) with DLBCL experienced
B-cell recovery (CD19+ B-cell count ≥ 0.07 × 10^9/L).

Discussion
GERSHWIN showed that obinutuzumab monotherapy
has acceptable safety and tolerability profiles in Chinese
patients with relapsed/refractory B-cell lymphomas; no
new safety signals were observed. Obinutuzumab also
showed encouraging efficacy, particularly in subjects with
CLL.

Consistent with previous reports in Caucasian popula-
tions [21], IRRs, pyrexia, and cough were the most com-
mon AEs in all three disease types in the current study. All
IRRs occurred during or within 24 h after the end of the
obinutuzumab infusion; all were grade I or II, and manage-
able. The rate of IRRs appeared to be highest in patients
with CLL (58.3%). Recent findings by Illidge et al. in [21]
and Freeman et al. in [22] suggest that CLL patients with
higher CD20+ expression are at greater risk of developing
severe IRRs to obinutuzumab. The IRR rate observed
in the current study was lower than reported by the GAU-
GUIN study despite similar intervention (monotherapy)
and patient characteristics (relapsed/refractory B-cell lymph-
omas). In GAUGUIN, the rate of IRR in patients with
relapsed/refractory CD20+ CLL was 100% (13/13 and
20/20 in phase I and II, respectively) [9]. In patients with
relapsed/refractory CD20+ DLBCL/mantle cell lymphoma
and indolent NHL in the GAUGUIN study, the IRR rate
was 75.0% and 72.5%, respectively, and the majority were
grade I or II and manageable [10, 11]. The IRR rate in our
study was also lower than that reported in a phase I dose-
finding study of obinutuzumab in 12 Japanese patients
with relapsed/refractory CD20+ NHL, in which all patients
experienced an IRR [23]. Awareness of recommended
measures to prevent the development of IRR and other
AEs during obinutuzumab therapy gained by some of the
investigators in the current study during previous clinical
trials may have contributed the lower IRR rate in the GER-
SHWIN study. However, it is important to note that such
comparisons are limited by the differences in patient
numbers and design between these studies. No TLS was
reported in the current study. Previous studies in Cauca-
sian patients, including CLL11 [12] and GAUGUIN [9, 11],
reported neutropenia as a major AE after obinutuzumab
treatment. In the current study, grade III–V neutropenia
was reported in three cases, but resolved spontaneously
or with treatment; none required dose adjustment/discon-
tinuation. One patient with CLL died of interstitial lung
disease on day 252 (82 days after the last dose of obinutu-
zumab); the infection started 60 days after the last dose and
was considered treatment-related.

Obinutuzumab efficacy in the current study was simi-
lar to that seen in non-Chinese patients in previous stud-
ies (e.g., GAUGUIN and the phase I Japanese dose-finding
study). The EoT response rate in the overall analysis was
33.3% (CLL: 58.3%; DLBCL: 13.0%; FL: 46.2%) and the
best overall response rate was 47.9% (CLL: 75.0%; DLBCL:
26.1%; FL: 61.5%). Most patients with CLL achieved a PR
at EoT (7/12; 58.3%). In GAUGUIN phase II (of relapsed/
refractory CD20+ indolent NHL patients; 85.0% had FL),
overall response rates ranged from 21.4% to 50.0% in the FL
subgroup (dependent on obinutuzumab dosage), and best
overall response rate ranged from 35.7% to 60.0% [11]. In
the phase I Japanese dose-finding study (66.7% of patients
had FL), the EoT response rate was 58.3% [23]. By com-
parison, in GAUGUIN phase II (in patients with relapsed/
refractory CD20+ DLBCL and mantle cell lymphoma,
62.5% DLBCL), EoT and best overall response rate in the
DLBCL subgroup were 28.0% and 32.0%, respectively [10].

Limitations of the current study include the small sam-
ple size (n = 48) and lack of a control arm. Nevertheless,
the results are encouraging and are generally comparable with
previous studies in non-Chinese patients.

Conclusions
The safety profile and efficacy of obinutuzumab monother-
apy in Chinese patients with CD20+ malignant B-cell lymph-
omas was similar to that observed in previous studies
in non-Chinese patient populations. No new safety signals
were observed.

Additional files

Additional file 1. Detailed inclusion and exclusion criteria.
Additional file 2. Study drug exposure.
Additional file 3. Incidence of AEs of any grade reported in ≥10% of
patients (in any patient population).
Additional file 4. Summary of patients with AEs NCI-CTCAE grade III–V.
Additional file 5. Summary of SAEs.
Abbreviations
AE: adverse event; AESI: AEs of special interest; CLL: chronic lymphocytic leukemia; CR: complete response; CRI: CR with incomplete bone marrow recovery; CRu: CR unconfirmed; DLBCL: diffuse large B-cell lymphoma; ECGs: electrocardiograms; EOT: end-of-treatment; FL: follicular lymphoma; HACA: human antichimeric antibodies; HAHAA: human antihuman antibodies; IRRs: infusion-related reactions; NHL: non-Hodgkin lymphoma; PFS: progression-free survival; PR: partial response; SAEs: serious AEs; SD: stable disease; TLS: tumor lysis syndrome; PD: progressive disease.

Authors’ contributions
Professor Y. Shi is the principal investigator. All authors contributed to the study design and data collection, and were responsible for the final interpretation of the data, development of the manuscript. All authors read and approved the final manuscript.

Author details
1 Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P. R. China. 2 Department of Lymphoma, Beijing Cancer Hospital, Peking University, Beijing 100142, P. R. China. 3 Department of Hematology, Ruijin Hospital, Shanghai Jiaotong University, Shanghai 200025, P. R. China. 4 Department of Hematology, Guangdong General Hospital/Guangdong Academy of Medical Sciences, Guangzhou 510030, Guangdong, P. R. China. 5 Clinical Science, Shanghai Roche Pharmaceuticals Ltd, Shanghai 201203, P. R. China. 6 Statistics, Roche (China) Holding Ltd, Shanghai 201203, P. R. China.

Acknowledgements
The authors thank all the patients who participated in the GERSHWIN study, and acknowledge all the study investigators and their staff. GERSHWIN was sponsored by F. Hoffmann-La Roche Ltd. Editorial support, under the direction of the lead author Y. Shi, was provided by Lucy Carrier and Elizabeth Johnson of Gardiner-Caldwell Communications, and Clare Cox (Ph.D.) of Edanz Medical Writing. Editorial support was funded by F. Hoffmann-La Roche Ltd.

Competing interests
Y. Shi, Y. Qin, Y. Song, X. Du, W. Ji, J. Zhu and Z. Shen have no potential competing interests to disclose. W. Hsu is employed by F. Hoffmann-La Roche Ltd. The GERSHWIN study was sponsored by F. Hoffmann-La Roche Ltd. The study sponsor designed the study and contributed to the collection, analysis, and interpretation of the data.

Availability of data and materials
The data that support the findings are held by F. Hoffmann-La Roche Ltd. Due to restrictions, the full dataset is not publicly available. Data supporting the conclusions of this article are included within the article and its additional files.

Ethics approval and consent to participate
The present study was approved by the Institutional Review Boards and/or Independent Ethics Committees of National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Cancer Hospital, Ruijin Hospital, Shanghai Jiaotong University, and Guangdong General Hospital/Guangdong Academy of Medical Sciences. It was conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonization guidelines for Good Clinical Practice.

Funding
GERSHWIN was sponsored by F. Hoffmann-La Roche Ltd. Medical Writing support, under the direction of the lead author, was provided by Elizabeth Johnson of Gardiner-Caldwell Communications, and was funded by F. Hoffmann-La Roche Ltd.

Received: 23 October 2017 Accepted: 28 March 2018 Published online: 30 May 2018

References
1. Mak V, Ip D, Mang O, Dalal C, Huang S, Gerrie A, et al. Preservation of lower incidence of chronic lymphocytic leukemia in Chinese residents in British Columbia: a 26-year survey from 1983 to 2008. Leuk Lymphoma. 2014;55(4):824–7.
2. Li QX, Li GD, Gao ZF, Zhou XG, Zhu XZ. Distribution pattern of lymphoma subtypes in China: a nationwide multicenter study of 10002 cases. J Diagn Concepts Pract. 2012;11(2):111–5.
3. Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin’s lymphoma. N Engl J Med. 2008;359(6):613–26.
4. Coiffier B, Haioun C, Ketterer N, Engert AA, Tilly H, Ma D, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood. 1998;92(6):1927–32.
5. McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczmaz MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16(8):2825–33.
6. Hainsworth JD, Litchy S, Barton JH, Houston GA, Hermann RC, Bradof JE, et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2003;21(9):1746–51.
7. Keating GM. Rituximab: a review of its use in chronic lymphocytic leukemia, low-grade or follicular lymphomas and diffuse B-cell lymphomas. Drugs. 2010;70(11):1445–76.
8. Grigg A, Dyer MJ, Gonzalez Diaz M, Dreyling M, Rule SL, Gei G, et al. Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma. Haematologica. 2017;102:765–72.
9. Cartron G, de Guibert S, Dihudy MS, Morschhauser F, Leblond V, Dupuis J, et al. Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study. Blood. 2014;124(14):2196–202.
10. Morschhauser F, Cartron G, Theiblemont C, Solal-Céligny P, Haioun C, Bouabdallah R, et al. Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large B-cell lymphoma or mantle cell lymphoma: results from the phase II GAUGUIN study. J Clin Oncol. 2013;31(23):2920–6.
11. Salles GA, Morschhauser F, Solal-Céligny P, Theiblemont C, Lamy T, Tilly H, et al. Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin's lymphoma: results of the phase II GAUGUIN study. J Clin Oncol. 2013;31(23):2920–6.
12. Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101–10.
13. Goede V, Fischer K, Engelke A, Schlag R, Lepretre S, Montero LF, et al. Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: final data from the phase II GAUGUIN study. Blood. 2014;124(14):2196–202.
14. Guido V, Fischer K, Eichhorst B, Wendtner CM, et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent B-cell non-Hodgkin lymphoma: final analysis of the GAUSS study. J Clin Oncol. 2015;33(33):3467–74.
15. Sehn LH, Chua N, Mayer J, Dueck G, Trněný M, Bouabdallah K, et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol. 2016;17(8):1081–93.
16. Zhai J, Qin Y, Zhu J, Song Y, Shen Z, Du X, et al. Pharmacokinetics of obinutuzumab in Chinese patients with B-cell lymphoma. Br J Clin Pharmacol. 2017. https://doi.org/10.1111/bcp.13232 (Epub ahead of print).
17. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol. 1999;17(4):1244–53.
18. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia.
Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 Guidelines. Blood. 2008;111(12):5446–56.

21. Illidge T, Klein C, Sehn LH, Davies A, Salles G, Cartron G. Obinutuzumab in hematologic malignancies: lessons learned to date. Cancer Treat Rev. 2015;41(9):784–92.

22. Freeman CL, Dixon M, Houghton R, Kreuzer KA, Fingerle-Rowson G, Herling M, et al. Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab. Leukemia. 2016;30(8):1763–6.

23. Ogura M, Tobinai K, Hatake K, Uchida T, Suzuki T, Kobayashi Y, et al. Phase I study of obinutuzumab (GA101) in Japanese patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Cancer Sci. 2013;104(1):105–10.